文献速递眼底病与葡萄膜炎

受海洋天然产物启发的Apratoxin S4:眼部血管生成疾病的新治疗选择

Apratoxin S4 Inspired by a Marine Natural Product, a New Treatment Option for Ocular Angiogenic Diseases.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

本研究探讨Apratoxin S4在眼部血管生成中的疗效与机制。体外实验显示其通过抑制多条血管生成通路强效抑制视网膜血管细胞活化,VEGF激活的血管细胞和血管对其更敏感。小鼠氧诱导视网膜病变、激光诱导脉络膜新生血管及兔持续性视网膜新生血管模型显示,腹腔和玻璃体腔给药均可阻碍眼内新生血管,并与阿柏西普有联合抑制作用。

要点

  • Apratoxin S4通过抑制多条血管生成通路强效抑制视网膜血管细胞活化。
  • VEGF激活的血管细胞和血管比静息状态更易受Apratoxin S4影响。
  • 腹腔和玻璃体腔给药均能阻碍小鼠及兔模型眼内新生血管,并与阿柏西普有联合抑制效应。

核心结论

  • Apratoxin S4是一种强效抗血管生成药物,通过介导多条血管生成通路抑制视网膜内皮细胞和周细胞活化。

研究设计与样本

  • 体外研究视网膜血管细胞增殖、迁移和管样结构形成能力。
  • 离体采用主动脉环、脉络膜和跖骨实验研究Apratoxin S4在多细胞环境中对血管长出的影响。
  • 在氧诱导视网膜病变(OIR)和激光诱导脉络膜新生血管(CNV)小鼠模型及持续性视网膜新生血管(PRNV)兔模型中测试Apratoxin S4。
  • 采用蛋白质印迹和ELISA检测Apratoxin S4处理后关键血管生成调节因子的表达。

主要发现

  • Apratoxin S4通过抑制多条血管生成通路强效抑制视网膜血管细胞活化。
  • VEGF激活的血管细胞和血管生成中的血管比静息血管细胞和血管更易受Apratoxin S4影响。
  • 腹腔和玻璃体腔递送Apratoxin S4均能在体内阻碍眼部新生血管。
  • Apratoxin S4特异性减弱病理性眼部血管生成,并与标准治疗VEGF抑制剂药物(阿柏西普)表现出联合抑制效应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Abnormal blood vessel formation is a defining feature of many blinding eye diseases. Targeting abnormal angiogenesis by inhibiting VEGF has revolutionized the treatment of many ocular angiogenic diseases over the last decade. However, a substantial number of patients are refractory to anti-VEGF treatment or may develop resistance over time. The objective of this study was to determine the efficacy and the mechanism of action of Apratoxin S4 in ocular angiogenesis. METHODS: Retinal vascular cell proliferation, migration, and the ability to form tube-like structure were studied in vitro. Ex vivo aortic ring, choroid, and metatarsal assays were used to study Apratoxin S4's impact on vessel outgrowth in a multicellular environment. Apratoxin S4 was also tested in mouse models of oxygen-induced retinopathy (OIR) and laser-induced choroidal neovascularization (CNV), and in a rabbit model of persistent retinal neovascularization (PRNV). Western blot and ELISA were used to determine the expression of key angiogenic regulators after Apratoxin S4 treatment. RESULTS: Apratoxin S4 strongly inhibits retinal vascular cell activation by suppressing multiple angiogenic pathways. VEGF-activated vascular cells and angiogenic vessels are more susceptible to Apratoxin S4 treatment than quiescent vascular cells and vessels. Both intraperitoneal and intravitreal delivery of Apratoxin S4 are able to impede ocular neovascularization in vivo. Apratoxin S4 specifically attenuates pathological ocular angiogenesis and exhibits a combinatorial inhibitory effect with standard-of-care VEGF inhibitor drug (aflibercept). CONCLUSIONS: Apratoxin S4 is a potent antiangiogenic drug that inhibits the activation of retinal endothelial cells and pericytes through mediating multiple angiogenic pathways.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Qiu B, Tan A, Veluchamy AB, et al. Apratoxin S4 Inspired by a Marine Natural Product, a New Treatment Option for Ocular Angiogenic Diseases. Invest Ophthalmol Vis Sci. 2019. PMID: 31361305. doi:10.1167/iovs.19-26936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。